Literature DB >> 6284649

Elimination of bacteria in biliary tract infections during ceftizoxime therapy.

E B Helm, D Wurbs, R Haag, D Bentele, P M Shah.   

Abstract

A transpapillary indwelling catheter was inserted to prevent stone impaction in six female patients who were suffering from choledocholithiasis. The bile withdrawn via the catheter was infected on six occasions with Escherichia coli. In one of these cases Klebsiella sp. and in another Salmonella sp. were also identified. All bacteria were sensitive to ceftizoxime (the MIC was between 0.007 and 0.06 mg/l). The bacterial counts in the bile were determined before and during treatment by means of membrane filtration. In all six cases there was a rapid decline in the colony count. The concentration of ceftizoxime in bile samples was several times higher than the MIC of ceftizoxime for the corresponding pathogens. Overall, the therapeutic results with ceftizoxime were good. Three of eight pathogens were eliminated from the bile within eight to 24 hours. In one case a change of pathogen was seen after 24 hours. Forty-eight hours after beginning treatment, four of eight pathogens had been eliminated from the bile. After 72 hours the colony count in six patients was less than 10 pathogens/ml. In two patients a change of pathogen occurred; in one patient treatment had to be stopped after the first injection because of urticaria.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6284649     DOI: 10.1007/bf01816726

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  23 in total

1.  Bacterial isolates in cholecystitis and cholelithiasis.

Authors:  T Bergan; I Dobloug; I Liavåg
Journal:  Scand J Gastroenterol       Date:  1979       Impact factor: 2.423

2.  Infectious complications after surgery for biliary calculus. The significance of bacteria in the biliary tract.

Authors:  J Engström; C G Groth; G Lundh; B Lönnqvist
Journal:  Acta Chir Scand       Date:  1972

3.  Acute obstructive suppurative cholangitis.

Authors:  E J Hinchey; C E Couper
Journal:  Am J Surg       Date:  1969-01       Impact factor: 2.565

4.  Polymicrobial sepsis following endoscopic retrograde cholangiopancreatography.

Authors:  C O Elson; K Hattori; M O Blackstone
Journal:  Gastroenterology       Date:  1975-08       Impact factor: 22.682

5.  Percutaneous transhepatic biliary drainage: technique, results, and applications.

Authors:  J T Ferrucci; P R Mueller; W P Harbin
Journal:  Radiology       Date:  1980-04       Impact factor: 11.105

6.  Acute suppurative cholangitis. Experience with 15 consecutive cases.

Authors:  A P Haupert; L C Carey; W E Evans; E H Ellison
Journal:  Arch Surg       Date:  1967-04

7.  Complications of endoscopic retrograde cholangiopancreatography (ERCP). A study of 10,000 cases.

Authors:  M K Bilbao; C T Dotter; T G Lee; R M Katon
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

8.  [Antibacterial activity of antibiotics in human bile (author's transl)].

Authors:  E B Helm; I Paulus; P M Shah; W Stille
Journal:  Infection       Date:  1976       Impact factor: 3.553

9.  Antibiotics in biliary disease: the relative importance of antibiotic concentrations in the bile and serum.

Authors:  M R Keighley; R B Drysdale; A H Quoraishi; D W Burdon; J Alexander-Willians
Journal:  Gut       Date:  1976-07       Impact factor: 23.059

10.  Antibacterial activity of ceftizoxime, a beta-lactamase-stable cephalosporin.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

View more
  3 in total

1.  Pharmacokinetics of ceftizoxime.

Authors:  U Gundert-Remy; R Hildebrandt; A Stiehl; P Schlegel
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

2.  Experimental studies of biliary excretion of piperacillin.

Authors:  P Calhoun; K B Brown; R Strunk; D A Krusch; W M Scheld; J B Hanks
Journal:  Ann Surg       Date:  1987-04       Impact factor: 12.969

Review 3.  Ceftizoxime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Richards; R C Heel
Journal:  Drugs       Date:  1985-04       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.